Company
Headquarters: Chicago, IL, United States
Employees: 172
CEO: Mr. Paul R. Edick
$338.4 Million
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. It markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis. The company also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Xeris Biopharma Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: XERS wb_incandescent
Stock: FSX: 2B3 wb_incandescent
Stock: Munich: 2B3 wb_incandescent